Qiagen Plans to Have Aggressive M&A Stance In '07; Inks Dx Deals With Pathway, Sequenom | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
SAN FRANCISCO — Qiagen plans to be aggressive in the mergers and acquisitions market this year and the firm believes the rapid emergence of molecular diagnostics will drive greater sales growth, CEO Peer Schatz told BioCommerce Week in an interview last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.